

In the Claims

1. (Withdrawn) A method of screening drug candidates comprising:
 - a) providing a cell that expresses an expression profile gene encoding CHA4 or fragment thereof;
 - b) adding a drug candidate to said cell; and
 - c) determining the effect of said drug candidate on the expression of said expression profile gene.
2. (Withdrawn) A method according to claim 1 wherein said determining comprises comparing the level of expression in the absence of said drug candidate to the level of expression in the presence of said drug candidate.
3. (Withdrawn) A method of screening for a bioactive agent capable of binding to CHA4 or a fragment thereof, said method comprising:
 - a) combining said CHA4 or a fragment thereof and a candidate bioactive agent; and
 - b) determining the binding of said candidate agent to said CHA4 or a fragment thereof.
4. (Withdrawn) A method for screening for a bioactive agent capable of modulating the activity of CHA4, said method comprising:
 - a) combining CHA4 and a candidate bioactive agent; and
 - b) determining the effect of said candidate agent on the bioactivity of CHA4.
5. (Withdrawn) A method of evaluating the effect of a candidate cancer drug comprising:
 - a) administering said drug to a patient;
 - b) removing a cell sample from said patient; and
 - c) determining the expression of a gene encoding CHA4 or fragment thereof.
6. (Withdrawn) A method according to claim 5 further comprising comparing said expression profile to an expression profile of a healthy individual.

7. (Canceled).
8. (Withdrawn) An antibody which specifically binds to CHA4 or a fragment thereof.
9. (Withdrawn) The antibody of Claim 8, wherein said antibody is a monoclonal antibody.
10. (Withdrawn) The antibody of Claim 8, wherein said antibody is a humanized antibody.
11. (Withdrawn) The antibody of Claim 8, wherein said antibody is an antibody fragment.
12. (Withdrawn) The antibody of Claim 8, wherein said antibody modulates the bioactivity of CHA4.
13. (Withdrawn) The antibody of Claim 12, wherein said antibody is capable of inhibiting the bioactivity or neutralizing the effect of CHA4.
14. (Withdrawn) A method for screening for a bioactive agent capable of interfering with the binding of CHA4 or a fragment thereof and an antibody which binds to CHA4 or fragment thereof, said method comprising:
 - a) combining CHA4 or fragment thereof, a candidate bioactive agent and an antibody which binds to CHA4 or fragment thereof; and
 - b) determining the binding of CHA4 or fragment thereof and said antibody.
15. (Withdrawn) A method according to Claim 14, wherein said antibody is capable of inhibiting or neutralizing the bioactivity of CHA4.
16. (Withdrawn) A method for inhibiting the activity of CHA4, said method comprising binding an inhibitor to CHA4.

17. (Withdrawn) A method according to claim 16 wherein said inhibitor is an antibody.
18. (Withdrawn) A method of neutralizing the effect of CHA4 or a fragment thereof, comprising contacting an agent specific for said CHA4 or fragment thereof with said CHA4 or fragment thereof in an amount sufficient to effect neutralization.
19. (Withdrawn) A method of treating breast cancer and/or colorectal cancer comprising administering to a patient an inhibitor of CHA4.
20. (Withdrawn) A method according to claim 19 wherein said inhibitor is an antibody.
21. (Withdrawn) A method for localizing a therapeutic moiety to breast cancer and/or colorectal cancer tissue comprising exposing said tissue to an antibody to CHA4 or fragment thereof conjugated to said therapeutic moiety.
22. (Withdrawn) The method of Claim 21, wherein said therapeutic moiety is a cytotoxic agent.
23. (Withdrawn) The method of Claim 21, wherein said therapeutic moiety is a radioisotope.
24. (Withdrawn) A method of treating breast cancer or colorectal cancer comprising administering to an individual having said cancer an antibody to CHA4 or fragment thereof conjugated to a therapeutic moiety.
25. (Withdrawn) The method of Claim 24, wherein said therapeutic moiety is a cytotoxic agent.
26. (Withdrawn) The method of Claim 24, wherein said therapeutic moiety is a radioisotope.

27. (Withdrawn) A method for inhibiting breast cancer or colorectal cancer in a cell, wherein said method comprises administering to a cell a composition comprising antisense molecules to a nucleic acid of figure 1.
28. (Withdrawn) A biochip comprising one or more nucleic acid segments encoding CHA4 or a fragment thereof, wherein said biochip comprises fewer than 1000 nucleic acid probes.
29. (Withdrawn) A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising CHA4 or a fragment thereof.
30. (Withdrawn) A method of eliciting an immune response in an individual, said method comprising administering to said individual a composition comprising a nucleic acid encoding CHA4 or a fragment thereof.
31. (Canceled).
32. (Currently Amended) A method of ~~diagnosing detecting breast cancer or~~ colorectal cancer comprising:
- a) determining the expression of a nucleic acid that encodes an amino acid sequence ~~at least 95% identical to~~ of SEQ ID NO:2 in a first colorectal tissue sample of an first individual; and
 - b) comparing the expression of said nucleic acid in the first colorectal tissue sample to expression of said nucleic acid in a ~~second~~ normal colorectal tissue sample, wherein an increase in expression of said nucleic acid in the first colorectal tissue sample relative to the ~~second normal colorectal tissue~~ sample ~~provides a diagnosis of~~ indicates ~~breast cancer or~~ colorectal cancer in said ~~the first~~ individual.
33. (Currently Amended) The method of claim 32, wherein said ~~second~~ normal colorectal tissue sample is obtained from said ~~first~~ individual.

34-36. (Canceled).

37. (Currently Amended) The method of claim 32, wherein said ~~second~~ normal colorectal tissue sample is obtained from a second individual.

38-40. (Canceled).

41. (Previously Presented) The method of claim 32, wherein said nucleic acid comprises SEQ ID NO:1.

42. (Previously Presented) The method of claim 32, wherein said expression is measured using a labeled nucleic acid probe.

43. (Previously Presented) The method of claim 32, wherein said expression is measured utilizing a biochip.

44. (Currently Amended) A method for determining the prognosis of an individual with breast cancer or colorectal cancer comprising determining the expression of a nucleic acid ~~that encodes~~ an ~~the~~ amino acid sequence ~~at least 95% identical to~~ of SEQ ID NO:2 in a breast or colorectal tissue sample ~~from an~~ of said individual at different cellular states, wherein ~~a high~~ the level of expression of said ~~sequence~~ nucleic acid at different cellular states ~~indicates a poor~~ is used to determine the prognosis for of the individual.

45. (Previously Presented) The method of claim 44, wherein said nucleic acid comprises SEQ ID NO:1.

46. (Previously Presented) The method of claim 44, wherein said expression is measured using a labeled nucleic acid probe.

47. (Previously Presented) The method of claim 44, wherein said expression is measured utilizing a biochip.

48-51. (Canceled).

52. (New) A method of detecting breast cancer comprising:

a) determining the expression of a nucleic acid that encodes an amino acid sequence of SEQ ID NO:2 in a first breast tissue sample of an individual; and

b) comparing the expression of said nucleic acid in the first breast tissue sample to expression of said nucleic acid in a normal breast tissue sample, wherein an increase in expression of said nucleic acid in the first breast tissue sample relative to the normal breast tissue sample indicates breast cancer in said individual.

53. (New) The method of claim 52, wherein said normal breast tissue sample is obtained from said individual.

54. (New) The method of claim 32, wherein said normal breast tissue sample is obtained from a second individual.

55. (New) The method of claim 52, wherein said nucleic acid comprises SEQ ID NO:1.

56. (New) The method of claim 52, wherein said expression is measured using a labeled nucleic acid probe.

57. (New) The method of claim 52, wherein said expression is measured utilizing a biochip.